Medication-related osteonecrosis of the jaw in a breast cancer patient receiving denosumab for bone metastases: a case report

The use of bone-modifying agents in cancer patients to prevent skeletal-related complications associated with bone metastases has been linked to an increased risk of medication-related osteonecrosis of the jaw (MRONJ). In oncologic settings, bone-modifying agents are typically administered at higher doses and shorter intervals than those used for osteoporosis, thereby further elevating MRONJ risk. We report a case of MRONJ in a breast cancer patient receiving denosumab for metastatic bone disease, which was successfully managed with conservative treatment.